Clinical trial
Open Label Extension Study of AMX0035 in Patients With ALS
NCT03488524 · Amylyx Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT03488524 |
|---|---|
| Title | Open Label Extension Study of AMX0035 in Patients With ALS |
| Official title | Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis: Open-Label Extension |
| Acronym | CENTAUR-OLE |
| Lead sponsor | Amylyx Pharmaceuticals Inc., Industry |
| Collaborators | Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis, ALS |
| Intervention type | Drug |
| Interventions | AMX0035 |
| Enrollment | 90 |
| Start date | Mar 29, 2018 |
| Primary completion | Mar 1, 2021 |
| Completion | Mar 1, 2021 |
| First posted | Apr 5, 2018 |
| Last update posted | Aug 13, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: